


## Morrionside

## Chemical Properties

CAS No. :	25406-64-8
Formula:	C <sub>17</sub> H <sub>26</sub> O <sub>11</sub>
Molecular Weight:	406.38
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Morrionside would act as a regulator of hepatic inflammatory reactions and lipid metabolism in db/db mice. It exhibits protective effects against diabetic renal damage and human umbilical vein endothelial cells, by inhibiting hyperglycemia and oxidative stress. Morrionside can notably protect the brain from damage induced by focal cerebral ischemia which might be related to morrionside antioxidant and anti-apoptotic properties in the brain.
Targets(IC50)	Apoptosis, MMP, Pyroptosis

## Solubility Information

Solubility	DMSO: 55 mg/mL (135.34 mM), Sonication is recommended. Ethanol: 73 mg/mL (179.63 mM), Sonication is recommended. Pyridine, Methanol: Soluble, ( $< 1$ mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.92 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	2.4608 mL	12.3038 mL	24.6075 mL
5 mM	0.4922 mL	2.4608 mL	4.9215 mL
10 mM	0.2461 mL	1.2304 mL	2.4608 mL
50 mM	0.0492 mL	0.2461 mL	0.4922 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Xiong S, et al. J Pharmacol Sci. 2015 Apr;127(4):414-8.

Li X, Xiang C, Zhu S, et al. SNX8 enables lysosome reformation and reverses lysosomal storage disorder. Nature Communications. 2024, 15(1): 2553.

Sun FL, et al. Eur J Pharmacol. 2014 Sep 5;738:214-21.

Cheng L, et al. J Cell Mol Med. 2015 Aug;19(8):1877-86.

Sun FL, et al. PLoS One. 2014 Jun 30;9(6):e1201194.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E\_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481